Nick  Leschly net worth and biography

Nick Leschly Biography and Net Worth

CEO of 2seventy bio
Nick Leschly is chief executive officer at 2seventy bio. Previously, Nick served as chief bluebird at bluebird bio for 11 years. Prior to bluebird, he was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development, and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for Velcade. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his M.B.A. from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

What is Nick Leschly's net worth?

The estimated net worth of Nick Leschly is at least $4.91 million as of January 5th, 2024. Mr. Leschly owns 1,085,476 shares of 2seventy bio stock worth more than $4,906,352 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Leschly may own. Additionally, Mr. Leschly receives an annual salary of $1,810,000.00 as CEO at 2seventy bio. Learn More about Nick Leschly's net worth.

How old is Nick Leschly?

Mr. Leschly is currently 51 years old. There are 2 older executives and no younger executives at 2seventy bio. Learn More on Nick Leschly's age.

What is Nick Leschly's salary?

As the CEO of 2seventy bio, Inc., Mr. Leschly earns $1,810,000.00 per year. Learn More on Nick Leschly's salary.

How do I contact Nick Leschly?

The corporate mailing address for Mr. Leschly and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on Nick Leschly's contact information.

Has Nick Leschly been buying or selling shares of 2seventy bio?

Nick Leschly has not been actively trading shares of 2seventy bio during the past quarter. Most recently, Nick Leschly sold 1,554 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.75, for a transaction totalling $5,827.50. Following the completion of the sale, the chief executive officer now directly owns 1,085,476 shares of the company's stock, valued at $4,070,535. Learn More on Nick Leschly's trading history.

Who are 2seventy bio's active insiders?

2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.

Are insiders buying or selling shares of 2seventy bio?

During the last twelve months, 2seventy bio insiders bought shares 3 times. They purchased a total of 716,414 shares worth more than $3,658,127.44. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 177,739 shares worth more than $768,902.01. The most recent insider tranaction occured on March, 25th when Director Casdin Capital, Llc bought 330,000 shares worth more than $1,673,100.00. Insiders at 2seventy bio own 2.6% of the company. Learn More about insider trades at 2seventy bio.

Information on this page was last updated on 3/25/2024.

Nick Leschly Insider Trading History at 2seventy bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2024Sell1,554$3.75$5,827.501,085,476View SEC Filing Icon  
1/3/2024Sell72,312$3.87$279,847.441,087,030View SEC Filing Icon  
8/22/2023Sell9,312$5.49$51,122.881,159,342View SEC Filing Icon  
8/3/2023Sell9,060$6.13$55,537.801,168,654View SEC Filing Icon  
1/12/2023Sell6,587$10.46$68,900.02536,419View SEC Filing Icon  
1/9/2023Sell2,979$10.33$30,773.07543,006View SEC Filing Icon  
8/5/2022Sell5,499$16.23$89,248.77545,985View SEC Filing Icon  
7/15/2022Sell5,404$13.81$74,629.24551,484View SEC Filing Icon  
1/7/2022Sell3,270$23.91$78,185.70View SEC Filing Icon  
See Full Table

Nick Leschly Buying and Selling Activity at 2seventy bio

This chart shows Nick Leschly's buying and selling at 2seventy bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

2seventy bio Company Overview

2seventy bio logo
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.52
Low: $4.46
High: $4.76

50 Day Range

MA: $5.18
Low: $3.96
High: $6.00

2 Week Range

Now: $4.52
Low: $1.53
High: $12.69

Volume

608,615 shs

Average Volume

1,139,501 shs

Market Capitalization

$231.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84